ES2062549T3 - Proteina anticoagulante. - Google Patents

Proteina anticoagulante.

Info

Publication number
ES2062549T3
ES2062549T3 ES90912756T ES90912756T ES2062549T3 ES 2062549 T3 ES2062549 T3 ES 2062549T3 ES 90912756 T ES90912756 T ES 90912756T ES 90912756 T ES90912756 T ES 90912756T ES 2062549 T3 ES2062549 T3 ES 2062549T3
Authority
ES
Spain
Prior art keywords
pct
epi
novel
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90912756T
Other languages
English (en)
Inventor
Jesper Skou Rasmussen
Ole Juul Nordfang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2062549T3 publication Critical patent/ES2062549T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

SE PRESENTAN NUEVOS ANALOGOS DE EPI EN DONDE SE HAN ELIMINADO UNO O MAS DE LOS RESIDUOS AMINOACIDOS DEL EPI NATIVO. UN GRUPO PREFERENTE DE LOS NUEVOS ANALOGOS DE EPI NO TIENE CAPACIDAD DE ENLACE A LA HEPARINA O TIENE MUY POCA. LOS NUEVOS ANALOGOS DE EPI SE PUEDEN UTILIZAR PARA EL TRATAMIENTO DE PACIENTES QUE PADECEN PROBLEMAS DE COAGULACION O CANCER.
ES90912756T 1989-08-18 1990-08-17 Proteina anticoagulante. Expired - Lifetime ES2062549T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK408089A DK408089D0 (da) 1989-08-18 1989-08-18 Proteiner

Publications (1)

Publication Number Publication Date
ES2062549T3 true ES2062549T3 (es) 1994-12-16

Family

ID=8129972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90912756T Expired - Lifetime ES2062549T3 (es) 1989-08-18 1990-08-17 Proteina anticoagulante.

Country Status (9)

Country Link
US (1) US5312736A (es)
EP (1) EP0487591B1 (es)
JP (1) JP3122127B2 (es)
AT (1) ATE97918T1 (es)
AU (1) AU6285290A (es)
DE (1) DE69004966T2 (es)
DK (2) DK408089D0 (es)
ES (1) ES2062549T3 (es)
WO (1) WO1991002753A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK148890D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
PT643585E (pt) * 1992-06-01 2000-05-31 Chiron Corp Utilizacao de inibidor da coagulacao associado a lipoproteinas (laci) para a preparacao de um medicamento para o tratamento de inflamacao aguda ou cronica
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
ZA941414B (en) * 1993-03-02 1994-09-28 Novo Nordisk A G Non-glycosylated TFPI analogues
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5650391A (en) * 1994-03-21 1997-07-22 Jewish Hospital Of St. Louis Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
JP3779728B2 (ja) * 1994-08-05 2006-05-31 カイロン コーポレイション 組織因子活性インヒビターの産生
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
AU711405B2 (en) * 1994-10-18 1999-10-14 Dendreon Corporation Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
US5977057A (en) 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
DK1140150T3 (da) * 1998-12-22 2004-03-22 Bayer Ag Fremgangsmåde til accelerering af hastigheden af mucociliær clearance under anvendelse af en serinproteaseinhibitor af Kunitz-type
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
AU2003267967B2 (en) * 2002-06-18 2008-11-20 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006066960A1 (en) * 2004-12-23 2006-06-29 Ludwig-Maximilians- Universität München Variant tfpi with increased anti-thrombotic activity
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
WO2007014749A2 (en) * 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CA2744235A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
CA2823776A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US12528880B2 (en) 2020-01-13 2026-01-20 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor

Also Published As

Publication number Publication date
JPH04507252A (ja) 1992-12-17
DE69004966D1 (de) 1994-01-13
ATE97918T1 (de) 1993-12-15
DK408089D0 (da) 1989-08-18
WO1991002753A1 (en) 1991-03-07
EP0487591B1 (en) 1993-12-01
AU6285290A (en) 1991-04-03
JP3122127B2 (ja) 2001-01-09
DK0487591T3 (da) 1994-04-18
US5312736A (en) 1994-05-17
DE69004966T2 (de) 1994-03-24
EP0487591A1 (en) 1992-06-03

Similar Documents

Publication Publication Date Title
ES2062549T3 (es) Proteina anticoagulante.
DE3884622D1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
DK83092D0 (da) Fremgangsmaade til udvinding af thrombin
DE69005347D1 (de) Absaugkanüle für chirurgische Zwecke, insbesondere für Fettabsaugung.
ES2070322T3 (es) Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
MY102806A (en) Human interleukin-3 and muteins thereof
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
ES2103305T3 (es) Produccion de inhibidor de interleuquina-1 humana recombinada.
FI904951A0 (fi) Vaevnadsplasminogenaktivatorderivat.
SE8902532D0 (sv) Bestaemning av plasmaproteiner
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
HUP9900506A2 (hu) Protrombinszármazékok
NZ235497A (en) Peptides (possibly related to hirudin) and pharmaceutical compositions for reducing blood coagulation
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DE58907930D1 (de) Amblyommin, ein neuer Wirkstoff für die Antikoagulationstherapie.
MX9305901A (es) Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
FI881124A7 (fi) Menetelmä proteiinin PP4 uuttamiseksi kudoksista ja sitruunahapon käyttö tähän tarkoitukseen.
DE3886092D1 (de) Behälter für einen extrakorporalen Blutbehandlungskreislauf.
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.
DE69002383D1 (de) Zusammensetzung zur heilung von autoimmunkrankheiten.
BR8801129A (pt) Suporte ou apoio de mesa para cartas de jogar,ou para pedras do jogo de domino

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 487591

Country of ref document: ES